{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:48:26Z","timestamp":1792104506919,"version":"4.4.0"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41591-026-04654-6","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:02:26Z","timestamp":1789981346000},"page":"3578-3594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A consensus-based guideline for personalized bacteriophage therapy"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0787-3894","authenticated-orcid":false,"given":"Silvia","family":"W\u00fcrstle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone C.","family":"Lieberknecht-Jouy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"D\u00fcchting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"L\u00f6\u00dfner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7735-8316","authenticated-orcid":false,"given":"Pieter-Jan","family":"Ceyssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6863-5219","authenticated-orcid":false,"given":"Jean-Paul","family":"Pirnay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5084-8059","authenticated-orcid":false,"given":"Mathieu","family":"de Jode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-7753","authenticated-orcid":false,"given":"Shawna","family":"McCallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5764-3494","authenticated-orcid":false,"given":"Lorenz","family":"Leitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Willy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Leptihn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke","family":"Korf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4207-5290","authenticated-orcid":false,"given":"Evgeny A.","family":"Idelevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9787-5633","authenticated-orcid":false,"given":"Martin","family":"Witzenrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6003-5024","authenticated-orcid":false,"given":"Timo","family":"Faltus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ruth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Blume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Fickenscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8157-2753","authenticated-orcid":false,"given":"Mathias W.","family":"Pletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Hafkemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Krut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Hartwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0324-7781","authenticated-orcid":false,"given":"Ulrich","family":"Matt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3496-345X","authenticated-orcid":false,"given":"Rebecca L.","family":"Knoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7050-797X","authenticated-orcid":false,"given":"M\u00fcnevver","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hammerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Barbirz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Bugert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Kempe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J. G. T.","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2905-5139","authenticated-orcid":false,"given":"Annika Y.","family":"Classen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the guideline group \u2018Personalized Bacteriophage Therapy\u2019 of the Association of the Scientific Medical Societies in Germany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"de Jode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Alt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Bend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus","family":"Gro\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Heider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Maelteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Nothacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Quax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Rajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Wittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Ziehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Zumpfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"4654_CR1","first-page":"329","volume":"7","author":"F D\u2019Herelle","year":"1931","unstructured":"D\u2019Herelle, F. Bacteriophage as a treatment in acute medical and surgical infections. Bull. N. Y. Acad. Med. 7, 329\u2013348 (1931).","journal-title":"Bull. N. Y. Acad. Med."},{"key":"4654_CR2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.resmic.2007.07.005","volume":"158","author":"F D\u2019Herelle","year":"2007","unstructured":"D\u2019Herelle, F. On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D\u2019Herelle, presented by Mr. Roux. Res. Microbiol. 158, 553\u2013554 (2007).","journal-title":"Res. Microbiol."},{"key":"4654_CR3","first-page":"195","volume":"1","author":"F D\u2019Herelle","year":"1929","unstructured":"D\u2019Herelle, F. Studies upon asiatic cholera. Yale J. Biol. Med. 1, 195\u2013219 (1929).","journal-title":"Yale J. Biol. Med."},{"key":"4654_CR4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jhmas\/jry024","volume":"73","author":"D Myelnikov","year":"2018","unstructured":"Myelnikov, D. An alternative cure: the adoption and survival of bacteriophage therapy in the USSR, 1922\u22121955. J. Hist. Med. Allied Sci. 73, 385\u2013411 (2018).","journal-title":"J. Hist. Med. Allied Sci."},{"key":"4654_CR5","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1084\/jem.45.5.887","volume":"45","author":"J Bronfenbrenner","year":"1927","unstructured":"Bronfenbrenner, J. & Muckenfuss, R. Studies on the bacteriophage of d\u2019Herelle: VIII. The mechanism of lysis of dead bacteria in the presence of bacteriophage. J. Exp. Med. 45, 887\u2013909 (1927).","journal-title":"J. Exp. Med."},{"key":"4654_CR6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-12-394438-2.00001-3","volume":"83","author":"N Chanishvili","year":"2012","unstructured":"Chanishvili, N. Phage therapy\u2014history from Twort and d\u2019Herelle through Soviet experience to current approaches. Adv. Virus Res. 83, 3\u201340 (2012).","journal-title":"Adv. Virus Res."},{"key":"4654_CR7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4161\/bact.1.1.14942","volume":"1","author":"MR Clokie","year":"2011","unstructured":"Clokie, M. R., Millard, A. D., Letarov, A. V. & Heaphy, S. Phages in nature. Bacteriophage 1, 31\u201345 (2011).","journal-title":"Bacteriophage"},{"key":"4654_CR8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nrmicro1750","volume":"5","author":"CA Suttle","year":"2007","unstructured":"Suttle, C. A. Marine viruses\u2014major players in the global ecosystem. Nat. Rev. Microbiol. 5, 801\u2013812 (2007).","journal-title":"Nat. Rev. Microbiol."},{"key":"4654_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41586-020-2007-4","volume":"578","author":"B Al-Shayeb","year":"2020","unstructured":"Al-Shayeb, B. et al. Clades of huge phages from across Earth\u2019s ecosystems. Nature 578, 425\u2013431 (2020).","journal-title":"Nature"},{"key":"4654_CR10","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/s41564-021-00980-2","volume":"6","author":"ND Youngblut","year":"2021","unstructured":"Youngblut, N. D. et al. Vertebrate host phylogeny influences gut archaeal diversity. Nat. Microbiol. 6, 1443\u20131454 (2021).","journal-title":"Nat. Microbiol."},{"key":"4654_CR11","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg4015","volume":"9","author":"M Wielscher","year":"2023","unstructured":"Wielscher, M. et al. The phageome in normal and inflamed human skin. Sci. Adv. 9, eadg4015 (2023).","journal-title":"Sci. Adv."},{"key":"4654_CR12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.chom.2019.01.017","volume":"25","author":"AN Shkoporov","year":"2019","unstructured":"Shkoporov, A. N. & Hill, C. Bacteriophages of the human gut: the \u2018known unknown\u2019 of the microbiome. Cell Host Microbe 25, 195\u2013209 (2019).","journal-title":"Cell Host Microbe"},{"key":"4654_CR13","volume":"81","author":"Z Cao","year":"2022","unstructured":"Cao, Z. et al. The gut virome: a new microbiome component in health and disease. EBioMedicine 81, 104113 (2022).","journal-title":"EBioMedicine"},{"key":"4654_CR14","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/ismej.2017.16","volume":"11","author":"C Howard-Varona","year":"2017","unstructured":"Howard-Varona, C., Hargreaves, K. R., Abedon, S. T. & Sullivan, M. B. Lysogeny in nature: mechanisms, impact and ecology of temperate phages. ISME J. 11, 1511\u20131520 (2017).","journal-title":"ISME J."},{"key":"4654_CR15","doi-asserted-by":"crossref","first-page":"210188","DOI":"10.1098\/rsob.210188","volume":"11","author":"S M\u00e4ntynen","year":"2021","unstructured":"M\u00e4ntynen, S., Laanto, E., Oksanen, H. M., Poranen, M. M. & D\u00edaz-Mu\u00f1oz, S. L. Black box of phage-bacterium interactions: exploring alternative phage infection strategies. Open Biol. 11, 210188 (2021).","journal-title":"Open Biol."},{"key":"4654_CR16","unstructured":"Phage therapy medicinal products (general chapter 5.31). In European Pharmacopoeia, 11th edn, Supplement 11.6. https:\/\/www.edqm.eu\/documents\/52006\/277566\/European%20Pharmacopoeia%20-%20Phage%20therapy%20medicinal%20products%20%285.31%29.pdf\/d9da2e01-e002-32c9-b2eb-8a9360439c05?t=1727862827906 (Council of Europe, 2024)."},{"key":"4654_CR17","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s11095-014-1617-7","volume":"32","author":"JP Pirnay","year":"2015","unstructured":"Pirnay, J. P. et al. Quality and safety requirements for sustainable phage therapy products. Pharm. Res. 32, 2173\u20132179 (2015).","journal-title":"Pharm. Res."},{"key":"4654_CR18","volume":"66","author":"GA Suh","year":"2022","unstructured":"Suh, G. A. et al. Considerations for the use of phage therapy in clinical practice. Antimicrob. Agents Chemother. 66, e0207121 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"4654_CR19","doi-asserted-by":"crossref","unstructured":"Liu, D. et al. The safety and toxicity of phage therapy: a review of animal and clinical studies. Viruses 13, 1268 (2021).","DOI":"10.3390\/v13071268"},{"key":"4654_CR20","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S1473-3099(21)00612-5","volume":"22","author":"S Uyttebroek","year":"2022","unstructured":"Uyttebroek, S. et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect. Dis. 22, e208\u2013e220 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"4654_CR21","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41564-024-01705-x","volume":"9","author":"J-P Pirnay","year":"2024","unstructured":"Pirnay, J.-P. et al. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nat. Microbiol. 9, 1434\u20131453 (2024).","journal-title":"Nat. Microbiol."},{"key":"4654_CR22","doi-asserted-by":"crossref","unstructured":"Stacey, H. J., De Soir, S. & Jones, J. D. The safety and efficacy of phage therapy: a systematic review of clinical and safety trials. Antibiotics (Basel) 11, 1340 (2022).","DOI":"10.3390\/antibiotics11101340"},{"key":"4654_CR23","unstructured":"EudraLex \u2212 Volume 4 \u2013 Good Manufacturing Practice (GMP) guidelines. European Commission https:\/\/health.ec.europa.eu\/medicinal-products\/eudralex\/eudralex-volume-4_en (2022)."},{"key":"4654_CR24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1473-3099(20)30330-3","volume":"21","author":"L Leitner","year":"2021","unstructured":"Leitner, L. et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect. Dis. 21, 427\u2013436 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"4654_CR25","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jamaoto.2019.1191","volume":"145","author":"ML Ooi","year":"2019","unstructured":"Ooi, M. L. et al. Safety and tolerability of bacteriophage therapy for chronic rhinosinusitis due to Staphylococcus aureus. JAMA Otolaryngol. Head Neck Surg. 145, 723\u2013729 (2019).","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"4654_CR26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1473-3099(18)30482-1","volume":"19","author":"P Jault","year":"2019","unstructured":"Jault, P. et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1\/2 trial. Lancet Infect. Dis. 19, 35\u201345 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"4654_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41329-z","volume":"14","author":"K Wortelboer","year":"2023","unstructured":"Wortelboer, K. et al. Phage-microbe dynamics after sterile faecal filtrate transplantation in individuals with metabolic syndrome: a double-blind, randomised, placebo-controlled clinical trial assessing efficacy and safety. Nat. Commun. 14, 5600 (2023).","journal-title":"Nat. Commun."},{"key":"4654_CR28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ebiom.2015.12.023","volume":"4","author":"SA Sarker","year":"2016","unstructured":"Sarker, S. A. et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 4, 124\u2013137 (2016).","journal-title":"EBioMedicine"},{"key":"4654_CR29","doi-asserted-by":"crossref","first-page":"237","DOI":"10.12968\/jowc.2009.18.6.42801","volume":"18","author":"DD Rhoads","year":"2009","unstructured":"Rhoads, D. D. et al. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J. Wound Care 18, 237\u2013238, 240\u2212243 (2009).","journal-title":"J. Wound Care"},{"key":"4654_CR30","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.11.018","volume":"6","author":"R Nir-Paz","year":"2025","unstructured":"Nir-Paz, R. et al. Randomized double-blind study on safety and tolerability of TP-102 phage cocktail in patients with infected and non-infected diabetic foot ulcers. Med 6, 100565 (2025).","journal-title":"Med"},{"key":"4654_CR31","doi-asserted-by":"crossref","unstructured":"Van Nieuwenhuyse, B. et al. A case of in situ phage therapy against Staphylococcus aureus in a bone allograft polymicrobial biofilm infection: outcomes and phage-antibiotic interactions. Viruses 13, 1898 (2021).","DOI":"10.3390\/v13101898"},{"key":"4654_CR32","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1354681","volume":"14","author":"B Van Nieuwenhuyse","year":"2024","unstructured":"Van Nieuwenhuyse, B. et al. Case report: Personalized triple phage-antibiotic combination therapy to rescue necrotizing fasciitis caused by Panton-Valentine leukocidin-producing MRSA in a 12-year-old boy. Front. Cell. Infect. Microbiol. 14, 1354681 (2024).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"4654_CR33","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s41591-025-03678-8","volume":"31","author":"BK Chan","year":"2025","unstructured":"Chan, B. K. et al. Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis. Nat. Med. 31, 1494\u20131501 (2025).","journal-title":"Nat. Med."},{"key":"4654_CR34","doi-asserted-by":"crossref","unstructured":"Rubalskii, E. et al. Bacteriophage therapy for critical infections related to cardiothoracic surgery. Antibiotics (Basel) 9, 232 (2020).","DOI":"10.3390\/antibiotics9050232"},{"key":"4654_CR35","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jinf.2021.05.027","volume":"83","author":"T Tkhilaishvili","year":"2021","unstructured":"Tkhilaishvili, T. et al. Successful case of adjunctive intravenous bacteriophage therapy to treat left ventricular assist device infection. J. Infect. 83, e1\u2013e3 (2021).","journal-title":"J. Infect."},{"key":"4654_CR36","volume":"11","author":"V Alt","year":"2024","unstructured":"Alt, V. et al. Case report: Local bacteriophage therapy for fracture-related infection with polymicrobial multi-resistant bacteria: hydrogel application and postoperative phage analysis through metagenomic sequencing. Front. Med. (Lausanne) 11, 1428432 (2024).","journal-title":"Front. Med. (Lausanne)"},{"key":"4654_CR37","doi-asserted-by":"crossref","unstructured":"Tkhilaishvili, T., Winkler, T., M\u00fcller, M., Perka, C. & Trampuz, A. Bacteriophages as adjuvant to antibiotics for the treatment of periprosthetic joint infection caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 64, e00924-19 (2019).","DOI":"10.1128\/AAC.00924-19"},{"key":"4654_CR38","doi-asserted-by":"crossref","unstructured":"Paul, K. et al. Bacteriophage rescue therapy of a vancomycin-resistant Enterococcus faecium infection in a one-year-old child following a third liver transplantation. Viruses 13, 1785 (2021).","DOI":"10.3390\/v13091785"},{"key":"4654_CR39","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00113-017-0374-6","volume":"120","author":"D Vogt","year":"2017","unstructured":"Vogt, D. et al. [Beyond antibiotic therapy - Future antiinfective strategies - Update 2017]. Unfallchirurg 120, 573\u2013584 (2017).","journal-title":"Unfallchirurg"},{"key":"4654_CR40","doi-asserted-by":"crossref","unstructured":"McCallin, S., Sacher, J. C., Zheng, J. & Chan, B. K. Current state of compassionate phage therapy. Viruses 11, 343 (2019).","DOI":"10.3390\/v11040343"},{"key":"4654_CR41","doi-asserted-by":"crossref","first-page":"756","DOI":"10.2340\/17453674.2022.4579","volume":"93","author":"JB Doub","year":"2022","unstructured":"Doub, J. B. et al. Salphage: salvage bacteriophage therapy for a recalcitrant Klebsiella pneumoniae prosthetic shoulder infection\u2014a case report. Acta Orthop. 93, 756\u2013759 (2022).","journal-title":"Acta Orthop."},{"key":"4654_CR42","volume":"8","author":"T Ferry","year":"2021","unstructured":"Ferry, T. et al. Case report: Arthroscopic \u2018debridement antibiotics and implant retention\u2019 with local injection of personalized phage therapy to salvage a relapsing Pseudomonas aeruginosa prosthetic knee infection. Front. Med. (Lausanne) 8, 569159 (2021).","journal-title":"Front. Med. (Lausanne)"},{"key":"4654_CR43","doi-asserted-by":"crossref","unstructured":"Doub, J. B., Ng, V. Y., Wilson, E., Corsini, L. & Chan, B. K. Successful treatment of a recalcitrant staphylococcus epidermidis prosthetic knee infection with intraoperative bacteriophage therapy. Pharmaceuticals (Basel) 14, 231 (2021).","DOI":"10.3390\/ph14030231"},{"key":"4654_CR44","doi-asserted-by":"crossref","unstructured":"P\u00fcschel, A., Skusa, R., Bollensdorf, A. & Gross, J. Local treatment of driveline infection with bacteriophages. Antibiotics (Basel) 11, 1310 (2022).","DOI":"10.3390\/antibiotics11101310"},{"key":"4654_CR45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1146\/annurev-virology-091919-074551","volume":"8","author":"M Popescu","year":"2021","unstructured":"Popescu, M., Van Belleghem, J. D., Khosravi, A. & Bollyky, P. L. Bacteriophages and the immune system. Annu. Rev. Virol. 8, 415\u2013435 (2021).","journal-title":"Annu. Rev. Virol."},{"key":"4654_CR46","doi-asserted-by":"crossref","unstructured":"Van Belleghem, J. D., D\u0105browska, K., Vaneechoutte, M., Barr, J. J. & Bollyky, P. L. Interactions between bacteriophage, bacteria, and the mammalian immune system. Viruses 11, 10 (2018).","DOI":"10.3390\/v11010010"},{"key":"4654_CR47","doi-asserted-by":"crossref","unstructured":"Sweere, J. M. et al. Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection. Science 363, eaat9691 (2019).","DOI":"10.1126\/science.aat9691"},{"key":"4654_CR48","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2217\/fmb-2017-0049","volume":"12","author":"A G\u00f3rski","year":"2017","unstructured":"G\u00f3rski, A. et al. Phages and immunomodulation. Future Microbiol. 12, 905\u2013914 (2017).","journal-title":"Future Microbiol."},{"key":"4654_CR49","doi-asserted-by":"crossref","first-page":"S433","DOI":"10.1093\/cid\/ciad483","volume":"77","author":"A G\u00f3rski","year":"2023","unstructured":"G\u00f3rski, A., Mi\u0119dzybrodzki, R., Jo\u0144czyk-Matysiak, E., Kniotek, M. & Letkiewicz, S. Therapeutic phages as modulators of the immune response: practical implications. Clin. Infect. Dis. 77, S433\u2013S439 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"4654_CR50","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2217\/fmb-2019-0222","volume":"14","author":"A G\u00f3rski","year":"2019","unstructured":"G\u00f3rski, A., Mi\u0119dzybrodzki, R., Jo\u0144czyk-Matysiak, E., \u017baczek, M. & Borysowski, J. Phage-specific diverse effects of bacterial viruses on the immune system. Future Microbiol. 14, 1171\u20131174 (2019).","journal-title":"Future Microbiol."},{"key":"4654_CR51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/B978-0-12-394438-2.00002-5","volume":"83","author":"A G\u00f3rski","year":"2012","unstructured":"G\u00f3rski, A. et al. Phage as a modulator of immune responses: practical implications for phage therapy. Adv. Virus Res. 83, 41\u201371 (2012).","journal-title":"Adv. Virus Res."},{"key":"4654_CR52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-1-4939-7395-8_12","volume":"1693","author":"K D\u0105browska","year":"2018","unstructured":"D\u0105browska, K. Interaction of bacteriophages with the immune system: induction of bacteriophage-specific antibodies. Methods Mol. Biol. 1693, 139\u2013150 (2018).","journal-title":"Methods Mol. Biol."},{"key":"4654_CR53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00705-005-0641-7","volume":"151","author":"K Dabrowska","year":"2006","unstructured":"Dabrowska, K., Swita\u0142a-Jele\u0144, K., Opolski, A. & G\u00f3rski, A. Possible association between phages, Hoc protein, and the immune system. Arch. Virol. 151, 209\u2013215 (2006).","journal-title":"Arch. Virol."},{"key":"4654_CR54","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41586-024-08039-y","volume":"635","author":"T Zhang","year":"2024","unstructured":"Zhang, T. et al. A bacterial immunity protein directly senses two disparate phage proteins. Nature 635, 728\u2013735 (2024).","journal-title":"Nature"},{"key":"4654_CR55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2022.11.017","volume":"186","author":"SA Strathdee","year":"2023","unstructured":"Strathdee, S. A., Hatfull, G. F., Mutalik, V. K. & Schooley, R. T. Phage therapy: from biological mechanisms to future directions. Cell 186, 17\u201331 (2023).","journal-title":"Cell"},{"key":"4654_CR56","doi-asserted-by":"crossref","unstructured":"Mitropoulou, G. et al. Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations. Eur. Respir. Rev. 31, 220121 (2022).","DOI":"10.1183\/16000617.0121-2022"},{"key":"4654_CR57","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-394438-2.00003-7","volume":"83","author":"R Mi\u0119dzybrodzki","year":"2012","unstructured":"Mi\u0119dzybrodzki, R. et al. Clinical aspects of phage therapy. Adv. Virus Res. 83, 73\u2013121 (2012).","journal-title":"Adv. Virus Res."},{"key":"4654_CR58","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/QCO.0000000000000658","volume":"33","author":"S Aslam","year":"2020","unstructured":"Aslam, S. Bacteriophage therapy as a treatment option for transplant infections. Curr. Opin. Infect. Dis. 33, 298\u2013303 (2020).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"4654_CR59","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ijid.2008.01.006","volume":"12","author":"J Borysowski","year":"2008","unstructured":"Borysowski, J. & G\u00f3rski, A. Is phage therapy acceptable in the immunocompromised host? Int. J. Infect. Dis. 12, 466\u2013471 (2008).","journal-title":"Int. J. Infect. Dis."},{"key":"4654_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33294-w","volume":"13","author":"B Van Nieuwenhuyse","year":"2022","unstructured":"Van Nieuwenhuyse, B. et al. Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler. Nat. Commun. 13, 5725 (2022).","journal-title":"Nat. Commun."},{"key":"4654_CR61","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/ciac453","volume":"76","author":"RM Dedrick","year":"2023","unstructured":"Dedrick, R. M. et al. Phage therapy of mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease. Clin. Infect. Dis. 76, 103\u2013112 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"4654_CR62","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14787210.2022.1990755","volume":"20","author":"AR Howard-Jones","year":"2022","unstructured":"Howard-Jones, A. R., Iredell, J. R. & Khatami, A. Phage therapy in pediatrics: the way forward for difficult-to-treat infections? Expert Rev. Anti Infect. Ther. 20, 487\u2013491 (2022).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"4654_CR63","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","volume":"25","author":"RM Dedrick","year":"2019","unstructured":"Dedrick, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 25, 730\u2013733 (2019).","journal-title":"Nat. Med."},{"key":"4654_CR64","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202113936","volume":"13","author":"A Khatami","year":"2021","unstructured":"Khatami, A. et al. Bacterial lysis, autophagy and innate immune responses during adjunctive phage therapy in a child. EMBO Mol. Med. 13, e13936 (2021).","journal-title":"EMBO Mol. Med."},{"key":"4654_CR65","doi-asserted-by":"crossref","unstructured":"Lebeaux, D. et al. A case of phage therapy against pandrug-resistant Achromobacter xylosoxidans in a 12-year-old lung-transplanted cystic fibrosis patient. Viruses 13, 60 (2021).","DOI":"10.3390\/v13010060"},{"key":"4654_CR66","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/ppul.24945","volume":"55","author":"AB Gainey","year":"2020","unstructured":"Gainey, A. B. et al. Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Pediatr. Pulmonol. 55, 2990\u20132994 (2020).","journal-title":"Pediatr. Pulmonol."},{"key":"4654_CR67","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jpids\/pix056","volume":"7","author":"C Duplessis","year":"2018","unstructured":"Duplessis, C. et al. Refractory Pseudomonas bacteremia in a 2-year-old sterilized by bacteriophage therapy. J. Pediatric Infect. Dis. Soc. 7, 253\u2013256 (2018).","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"4654_CR68","first-page":"Ra126","volume":"14","author":"W Fortuna","year":"2008","unstructured":"Fortuna, W., Miedzybrodzki, R., Weber-Dabrowska, B. & G\u00f3rski, A. Bacteriophage therapy in children: facts and prospects. Med. Sci. Monit. 14, Ra126\u2013Ra132 (2008).","journal-title":"Med. Sci. Monit."},{"key":"4654_CR69","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3181\/00379727-113-28374","volume":"113","author":"JW Uhr","year":"1963","unstructured":"Uhr, J. W., Dancis, J. & Finkelstein, M. S. Passage of bacteriophage phi X 174 across the placenta in guinea pigs. Proc. Soc. Exp. Biol. Med. 113, 391\u2013394 (1963).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"4654_CR70","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3181\/00379727-101-24885","volume":"101","author":"AC Kulangara","year":"1959","unstructured":"Kulangara, A. C. & Sellers, M. I. Passage of bacteriophages from mother to foetus in the rat. Proc. Soc. Exp. Biol. Med. 101, 207\u2013211 (1959).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"4654_CR71","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2144\/04371ST04","volume":"37","author":"AS Srivastava","year":"2004","unstructured":"Srivastava, A. S., Chauhan, D. P. & Carrier, E. In utero detection of T7 phage after systemic administration to pregnant mice. Biotechniques 37, 81\u201383 (2004).","journal-title":"Biotechniques"},{"key":"4654_CR72","volume":"10","author":"GR Young","year":"2022","unstructured":"Young, G. R. et al. Optimisation and application of a novel method to identify bacteriophages in maternal milk and infant stool identifies host-phage communities within preterm infant gut. Front. Pediatr. 10, 856520 (2022).","journal-title":"Front. Pediatr."},{"key":"4654_CR73","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.3389\/fmicb.2017.02660","volume":"8","author":"LL Furfaro","year":"2017","unstructured":"Furfaro, L. L., Chang, B. J. & Payne, M. S. Applications for bacteriophage therapy during pregnancy and the perinatal period. Front. Microbiol. 8, 2660 (2017).","journal-title":"Front. Microbiol."},{"key":"4654_CR74","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41396-021-01090-x","volume":"16","author":"M Shamash","year":"2022","unstructured":"Shamash, M. & Maurice, C. F. Phages in the infant gut: a framework for virome development during early life. ISME J. 16, 323\u2013330 (2022).","journal-title":"ISME J."},{"key":"4654_CR75","unstructured":"Ligonenko, O. V. et al. [Application of bacteriophages in the complex treatment of shotgun wounds of soft tissues in patients suffering from multiple antibiotic allergies]. Klin. Khir. 65\u221266 (2015)."},{"key":"4654_CR76","unstructured":"Sakandelidze, V. M. [The combined use of specific phages and antibiotics in different infectious allergoses]. Vrach. Delo. 60\u221263 (1991)."},{"key":"4654_CR77","unstructured":"European Committee on Antimicrobial Susceptibility Testing. EUCAST https:\/\/www.eucast.org\/ast-of-phages (2026)."},{"key":"4654_CR78","unstructured":"Phagistry. Registry for patients receiving phage therapy. https:\/\/www.phagistry.org (2026)."},{"key":"4654_CR79","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.cell.2022.04.024","volume":"185","author":"JA Nick","year":"2022","unstructured":"Nick, J. A. et al. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell 185, 1860\u20131874 (2022).","journal-title":"Cell"},{"key":"4654_CR80","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3389\/fmicb.2020.01161","volume":"11","author":"L Bretaudeau","year":"2020","unstructured":"Bretaudeau, L., Tremblais, K., Aubrit, F., Meichenin, M. & Arnaud, I. Good Manufacturing Practice (GMP) compliance for phage therapy medicinal products. Front. Microbiol. 11, 1161 (2020).","journal-title":"Front. Microbiol."},{"key":"4654_CR81","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3389\/fmicb.2019.01674","volume":"10","author":"V Hietala","year":"2019","unstructured":"Hietala, V., Horsma-Heikkinen, J., Carron, A., Skurnik, M. & Kiljunen, S. The removal of endo- and enterotoxins from bacteriophage preparations. Front. Microbiol. 10, 1674 (2019).","journal-title":"Front. Microbiol."},{"key":"4654_CR82","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.mimet.2016.11.020","volume":"132","author":"JD Van Belleghem","year":"2017","unstructured":"Van Belleghem, J. D., Merabishvili, M., Vergauwen, B., Lavigne, R. & Vaneechoutte, M. A comparative study of different strategies for removal of endotoxins from bacteriophage preparations. J. Microbiol. Methods 132, 153\u2013159 (2017).","journal-title":"J. Microbiol. Methods"},{"key":"4654_CR83","doi-asserted-by":"crossref","first-page":"e4944","DOI":"10.1371\/journal.pone.0004944","volume":"4","author":"M Merabishvili","year":"2009","unstructured":"Merabishvili, M. et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE 4, e4944 (2009).","journal-title":"PLoS ONE"},{"key":"4654_CR84","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1038\/s41596-020-0346-0","volume":"15","author":"T Luong","year":"2020","unstructured":"Luong, T., Salabarria, A. C., Edwards, R. A. & Roach, D. R. Standardized bacteriophage purification for personalized phage therapy. Nat. Protoc. 15, 2867\u20132890 (2020).","journal-title":"Nat. Protoc."},{"key":"4654_CR85","unstructured":"Concept paper on the establishment of a guideline on the development and manufacture of human medicinal products specifically designed for phage therapy. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-quality-safety-and-efficacy-veterinary-medicinal-products-specifically-designed-phage-therapy_en.pdf (European Medicines Agency, 2023)."},{"key":"4654_CR86","doi-asserted-by":"crossref","unstructured":"Pirnay, J. P. et al. The magistral phage. Viruses 10, 64 (2018).","DOI":"10.3390\/v10020064"},{"key":"4654_CR87","doi-asserted-by":"crossref","unstructured":"Moraes de Souza, C., Tanir, T., Orellana, M., Escalante, A. & Koeris, M. S. Manufacturing bacteriophages (part 2 of 2): formulation, analytics and quality control considerations. Pharmaceuticals (Basel) 14, 895 (2021).","DOI":"10.3390\/ph14090895"},{"key":"4654_CR88","doi-asserted-by":"crossref","unstructured":"Rosner, D. & Clark, J. Formulations for bacteriophage therapy and the potential uses of immobilization. Pharmaceuticals (Basel) 14, 359 (2021).","DOI":"10.3390\/ph14040359"},{"key":"4654_CR89","doi-asserted-by":"crossref","unstructured":"Flint, R. et al. Stability considerations for bacteriophages in liquid formulations designed for nebulization. Cells 12, 2057 (2023).","DOI":"10.3390\/cells12162057"},{"key":"4654_CR90","first-page":"413","volume":"95","author":"F Winzig","year":"2022","unstructured":"Winzig, F. et al. Inhaled bacteriophage therapy for multi-drug resistant Achromobacter. Yale J. Biol. Med. 95, 413\u2013427 (2022).","journal-title":"Yale J. Biol. Med."},{"key":"4654_CR91","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cis.2017.05.014","volume":"249","author":"DJ Malik","year":"2017","unstructured":"Malik, D. J. et al. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv. Colloid. Interface Sci. 249, 100\u2013133 (2017).","journal-title":"Adv. Colloid. Interface Sci."},{"key":"4654_CR92","doi-asserted-by":"crossref","first-page":"139236","DOI":"10.1016\/j.ijbiomac.2024.139236","volume":"292","author":"C Karthika","year":"2025","unstructured":"Karthika, C., Malligarjunan, N., Pandian, S. K. & Gowrishankar, S. Chitosan-encapsulated bacteriophage cocktail as promising oral delivery system to surpass gastrointestinal infection caused by Klebsiella aerogenes. Int. J. Biol. Macromol. 292, 139236 (2025).","journal-title":"Int. J. Biol. Macromol."},{"key":"4654_CR93","volume":"24","author":"JAR Barros","year":"2020","unstructured":"Barros, J. A. R. et al. Encapsulated bacteriophages in alginate-nanohydroxyapatite hydrogel as a novel delivery system to prevent orthopedic implant-associated infections. Nanomedicine 24, 102145 (2020).","journal-title":"Nanomedicine"},{"key":"4654_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/srep41441","volume":"7","author":"J Colom","year":"2017","unstructured":"Colom, J. et al. Microencapsulation with alginate\/CaCO3: a strategy for improved phage therapy. Sci. Rep. 7, 41441 (2017).","journal-title":"Sci. Rep."},{"key":"4654_CR95","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-1-4939-7343-9_7","volume":"1681","author":"H Ahmadi","year":"2018","unstructured":"Ahmadi, H., Wang, Q., Lim, L. T. & Balamurugan, S. Encapsulation of Listeriaphage A511 by alginate to improve its thermal stability. Methods Mol. Biol. 1681, 89\u201395 (2018).","journal-title":"Methods Mol. Biol."},{"key":"4654_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-35364-5","volume":"13","author":"T Kielholz","year":"2023","unstructured":"Kielholz, T., Rohde, F., Jung, N. & Windbergs, M. Bacteriophage-loaded functional nanofibers for treatment of P. aeruginosa and S. aureus wound infections. Sci. Rep. 13, 8330 (2023).","journal-title":"Sci. Rep."},{"key":"4654_CR97","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.3389\/fmicb.2018.02172","volume":"9","author":"S Cinquerrui","year":"2018","unstructured":"Cinquerrui, S., Mancuso, F., Vladisavljevi\u0107, G. T., Bakker, S. E. & Malik, D. J. Nanoencapsulation of bacteriophages in liposomes prepared using microfluidic hydrodynamic flow focusing. Front. Microbiol. 9, 2172 (2018).","journal-title":"Front. Microbiol."},{"key":"4654_CR98","doi-asserted-by":"crossref","unstructured":"Moghtader, F., Solakoglu, S. & Piskin, E. Alginate- and chitosan-modified gelatin hydrogel microbeads for delivery of E. coli phages. Gels 10, 244 (2024).","DOI":"10.3390\/gels10040244"},{"key":"4654_CR99","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00203-024-04168-0","volume":"206","author":"N Mohan","year":"2024","unstructured":"Mohan, N., Bosco, K., Peter, A., Abhitha, K. & Bhat, S. G. Bacteriophage entrapment strategies for the treatment of chronic wound infections: a comprehensive review. Arch. Microbiol. 206, 443 (2024).","journal-title":"Arch. Microbiol."},{"key":"4654_CR100","doi-asserted-by":"crossref","first-page":"6583","DOI":"10.1021\/acsabm.4c00747","volume":"7","author":"AS Mary","year":"2024","unstructured":"Mary, A. S. et al. Formulation of dual-functional nonionic cetomacrogol creams incorporated with bacteriophage and human platelet lysate for effective targeting of MDR P. aeruginosa and enhanced wound healing. ACS Appl. Bio. Mater. 7, 6583\u20136593 (2024).","journal-title":"ACS Appl. Bio. Mater."},{"key":"4654_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-024-00552-2","volume":"10","author":"B Chen","year":"2024","unstructured":"Chen, B. et al. Combination of bacteriophages and vancomycin in a co-delivery hydrogel for localized treatment of fracture-related infections. NPJ Biofilms Microbiomes 10, 77 (2024).","journal-title":"NPJ Biofilms Microbiomes"},{"key":"4654_CR102","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1016\/j.xphs.2024.08.005","volume":"113","author":"HJ Coleman","year":"2024","unstructured":"Coleman, H. J. et al. Formulation of three tailed bacteriophages by spray-drying and atomic layer deposition for thermal stability and controlled release. J. Pharm. Sci. 113, 3238\u20133245 (2024).","journal-title":"J. Pharm. Sci."},{"key":"4654_CR103","doi-asserted-by":"crossref","unstructured":"Passerini, M., Petri, F. & Suh, G. A. Phage therapy for cardiac implantable electronic devices and vascular grafts: a targeted literature review. Pathogens 13, 424 (2024).","DOI":"10.3390\/pathogens13050424"},{"key":"4654_CR104","doi-asserted-by":"crossref","unstructured":"Rojas, S. V. et al. Bacteriophage-enriched galenic for intrapericardial ventricular assist device infection. Antibiotics (Basel) 11, 602 (2022).","DOI":"10.3390\/antibiotics11050602"},{"key":"4654_CR105","unstructured":"European Commission. Guideline on the readability of the labelling and package leaflet of medicinal products for human use. European Commission https:\/\/health.ec.europa.eu\/system\/files\/2016-11\/2009_01_12_readability_guideline_final_en_0.pdf (2009)."},{"key":"4654_CR106","unstructured":"US Food & Drug Administration. Bacterial Endotoxins\/Pyrogens. FDA https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/inspection-technical-guides\/bacterial-endotoxinspyrogens (2014)."},{"key":"4654_CR107","unstructured":"Pyrogenicity (general chapter 5.1.13). In European Pharmacopoeia 11th edn (European Directorate for the Quality of Medicines & HealthCare, 2025)."},{"key":"4654_CR108","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12223-011-0039-8","volume":"56","author":"E Jo\u0144czyk","year":"2011","unstructured":"Jo\u0144czyk, E., K\u0142ak, M., Mi\u0119dzybrodzki, R. & G\u00f3rski, A. The influence of external factors on bacteriophages\u2014review. Folia Microbiol. (Praha) 56, 191\u2013200 (2011).","journal-title":"Folia Microbiol. (Praha)"},{"key":"4654_CR109","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3390\/pharmaceutics14091936","volume":"14","author":"M Wdowiak","year":"2022","unstructured":"Wdowiak, M., Paczesny, J. & Raza, S. Enhancing the stability of bacteriophages using physical, chemical, and nano-based approaches: a review. Pharmaceutics 14, 1936 (2022).","journal-title":"Pharmaceutics"},{"key":"4654_CR110","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-1-4939-7395-8_18","volume":"1693","author":"JP Pirnay","year":"2018","unstructured":"Pirnay, J. P., Merabishvili, M., Van Raemdonck, H., De Vos, D. & Verbeken, G. Bacteriophage production in compliance with regulatory requirements. Methods Mol. Biol. 1693, 233\u2013252 (2018).","journal-title":"Methods Mol. Biol."},{"key":"4654_CR111","unstructured":"K\u00f6nig, H. & Sauter, A. Bakteriophagen in Medizin, Land- und Lebensmittelwirtschaft \u2013 Anwendungsperspektiven, Innovations- und Regulierungsfragen. Innovationsanalyse. KIT https:\/\/publikationen.bibliothek.kit.edu\/1000160512 (2023)."},{"key":"4654_CR112","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-1-4939-7395-8_9","volume":"1693","author":"M Merabishvili","year":"2018","unstructured":"Merabishvili, M., Pirnay, J. P. & De Vos, D. Guidelines to compose an ideal bacteriophage cocktail. Methods Mol. Biol. 1693, 99\u2013110 (2018).","journal-title":"Methods Mol. Biol."},{"key":"4654_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06422-1","volume":"12","author":"F Molina","year":"2022","unstructured":"Molina, F., Menor-Flores, M., Fern\u00e1ndez, L., Vega-Rodr\u00edguez, M. A. & Garc\u00eda, P. Systematic analysis of putative phage-phage interactions on minimum-sized phage cocktails. Sci. Rep. 12, 2458 (2022).","journal-title":"Sci. Rep."},{"key":"4654_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53994-9","volume":"15","author":"MK Kim","year":"2024","unstructured":"Kim, M. K. et al. A blueprint for broadly effective bacteriophage-antibiotic cocktails against bacterial infections. Nat. Commun. 15, 9987 (2024).","journal-title":"Nat. Commun."},{"key":"4654_CR115","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2217\/fmb.13.47","volume":"8","author":"BK Chan","year":"2013","unstructured":"Chan, B. K., Abedon, S. T. & Loc-Carrillo, C. Phage cocktails and the future of phage therapy. Future Microbiol. 8, 769\u2013783 (2013).","journal-title":"Future Microbiol."},{"key":"4654_CR116","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.538060","volume":"11","author":"SG Rotman","year":"2020","unstructured":"Rotman, S. G. et al. Local bacteriophage delivery for treatment and prevention of bacterial infections. Front. Microbiol. 11, 538060 (2020).","journal-title":"Front. Microbiol."},{"key":"4654_CR117","volume":"12","author":"YD Niu","year":"2021","unstructured":"Niu, Y. D. et al. Efficacy of individual bacteriophages does not predict efficacy of bacteriophage cocktails for control of Escherichia coli O157. Front. Microbiol. 12, 616712 (2021).","journal-title":"Front. Microbiol."},{"key":"4654_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52192-3","volume":"14","author":"S W\u00fcrstle","year":"2024","unstructured":"W\u00fcrstle, S. et al. Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University. Sci. Rep. 14, 2657 (2024).","journal-title":"Sci. Rep."},{"key":"4654_CR119","doi-asserted-by":"crossref","first-page":"101201","DOI":"10.1016\/j.coviro.2022.101201","volume":"53","author":"C Torres-Barcel\u00f3","year":"2022","unstructured":"Torres-Barcel\u00f3, C., Turner, P. E. & Buckling, A. Mitigation of evolved bacterial resistance to phage therapy. Curr. Opin. Virol. 53, 101201 (2022).","journal-title":"Curr. Opin. Virol."},{"key":"4654_CR120","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.1128\/AEM.00757-12","volume":"78","author":"AR Hall","year":"2012","unstructured":"Hall, A. R., De Vos, D., Friman, V. P., Pirnay, J. P. & Buckling, A. Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Appl. Environ. Microbiol. 78, 5646\u20135652 (2012).","journal-title":"Appl. Environ. Microbiol."},{"key":"4654_CR121","doi-asserted-by":"crossref","first-page":"R1120","DOI":"10.1016\/j.cub.2020.07.036","volume":"30","author":"AR Burmeister","year":"2020","unstructured":"Burmeister, A. R. & Turner, P. E. Trading-off and trading-up in the world of bacteria-phage evolution. Curr. Biol. 30, R1120\u2013R1124 (2020).","journal-title":"Curr. Biol."},{"key":"4654_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/srep26717","volume":"6","author":"BK Chan","year":"2016","unstructured":"Chan, B. K. et al. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep. 6, 26717 (2016).","journal-title":"Sci. Rep."},{"key":"4654_CR123","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/emph\/eoaa026","volume":"2020","author":"J Gurney","year":"2020","unstructured":"Gurney, J. et al. Phage steering of antibiotic-resistance evolution in the bacterial pathogen, Pseudomonas aeruginosa. Evol. Med. Public Health 2020, 148\u2013157 (2020).","journal-title":"Evol. Med. Public Health"},{"key":"4654_CR124","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-virology-012423-110530","volume":"10","author":"A Orom\u00ed-Bosch","year":"2023","unstructured":"Orom\u00ed-Bosch, A., Antani, J. D. & Turner, P. E. Developing phage therapy that overcomes the evolution of bacterial resistance. Annu. Rev. Virol. 10, 503\u2013524 (2023).","journal-title":"Annu. Rev. Virol."},{"key":"4654_CR125","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.chom.2019.01.014","volume":"25","author":"KE Kortright","year":"2019","unstructured":"Kortright, K. E., Chan, B. K., Koff, J. L. & Turner, P. E. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe 25, 219\u2013232 (2019).","journal-title":"Cell Host Microbe"},{"key":"4654_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52595-w","volume":"15","author":"F Kunisch","year":"2024","unstructured":"Kunisch, F. et al. Targeting Pseudomonas aeruginosa biofilm with an evolutionary trained bacteriophage cocktail exploiting phage resistance trade-offs. Nat. Commun. 15, 8572 (2024).","journal-title":"Nat. Commun."},{"key":"4654_CR127","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.medj.2024.05.017","volume":"5","author":"M Bernab\u00e9u-Gimeno","year":"2024","unstructured":"Bernab\u00e9u-Gimeno, M. et al. Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients. Med 5, 1096\u20131111 (2024).","journal-title":"Med"},{"key":"4654_CR128","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3389\/fmicb.2017.00467","volume":"8","author":"R Mi\u0119dzybrodzki","year":"2017","unstructured":"Mi\u0119dzybrodzki, R. et al. Means to facilitate the overcoming of gastric juice barrier by a therapeutic staphylococcal bacteriophage A5\/80. Front. Microbiol. 8, 467 (2017).","journal-title":"Front. Microbiol."},{"key":"4654_CR129","doi-asserted-by":"crossref","unstructured":"Le Guellec, S. et al. Administration of bacteriophages via nebulization during mechanical ventilation: in vitro study and lung deposition in macaques. Viruses 15, 602 (2023).","DOI":"10.3390\/v15030602"},{"key":"4654_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86571-x","volume":"11","author":"\u0141 Richter","year":"2021","unstructured":"Richter, \u0141 et al. Adsorption of bacteriophages on polypropylene labware affects the reproducibility of phage research. Sci. Rep. 11, 7387 (2021).","journal-title":"Sci. Rep."},{"key":"4654_CR131","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1749-4486.2009.01973.x","volume":"34","author":"A Wright","year":"2009","unstructured":"Wright, A., Hawkins, C. H., Angg\u00e5rd, E. E. & Harper, D. R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34, 349\u2013357 (2009).","journal-title":"Clin. Otolaryngol."},{"key":"4654_CR132","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(24)00424-9","volume":"24","author":"P Kim","year":"2024","unstructured":"Kim, P. et al. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. Lancet Infect. Dis. 24, 1319\u20131332 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"4654_CR133","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1016\/j.cell.2024.09.009","volume":"187","author":"M Koncz","year":"2024","unstructured":"Koncz, M. et al. Genomic surveillance as a scalable framework for precision phage therapy against antibiotic-resistant pathogens. Cell 187, 5901\u20135918 (2024).","journal-title":"Cell"},{"key":"4654_CR134","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00614-23","volume":"61","author":"K Parmar","year":"2023","unstructured":"Parmar, K. et al. Interlaboratory comparison of Pseudomonas aeruginosa phage susceptibility testing. J. Clin. Microbiol. 61, e0061423 (2023).","journal-title":"J. Clin. Microbiol."},{"key":"4654_CR135","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/jac\/dkae325","volume":"79","author":"C Kolenda","year":"2024","unstructured":"Kolenda, C., Jourdan, J., Roussel-Gaillard, T., Medina, M. & Laurent, F. Phage susceptibility testing methods or \u2018phagograms\u2019: where do we stand and where should we go? J. Antimicrob. Chemother. 79, 2742\u20132749 (2024).","journal-title":"J. Antimicrob. Chemother."},{"key":"4654_CR136","doi-asserted-by":"crossref","first-page":"e0118557","DOI":"10.1371\/journal.pone.0118557","volume":"10","author":"M Khan Mirzaei","year":"2015","unstructured":"Khan Mirzaei, M. & Nilsson, A. S. Isolation of phages for phage therapy: a comparison of spot tests and efficiency of plating analyses for determination of host range and efficacy. PLoS ONE 10, e0118557 (2015).","journal-title":"PLoS ONE"},{"key":"4654_CR137","volume":"12","author":"AJ Kunz Coyne","year":"2024","unstructured":"Kunz Coyne, A. J. et al. Exploring synergistic and antagonistic interactions in phage-antibiotic combinations against ESKAPE pathogens. Microbiol. Spectr. 12, e0042724 (2024).","journal-title":"Microbiol. Spectr."},{"key":"4654_CR138","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104045","volume":"80","author":"FL Gordillo Altamirano","year":"2022","unstructured":"Gordillo Altamirano, F. L. et al. Phage-antibiotic combination is a superior treatment against Acinetobacter baumanniiin a preclinical study. EBioMedicine 80, 104045 (2022).","journal-title":"EBioMedicine"},{"key":"4654_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20698-2","volume":"8","author":"L Ma","year":"2018","unstructured":"Ma, L., Green, S. I., Trautner, B. W., Ramig, R. F. & Maresso, A. W. Metals enhance the killing of bacteria by bacteriophage in human blood. Sci. Rep. 8, 2326 (2018).","journal-title":"Sci. Rep."},{"key":"4654_CR140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijfoodmicro.2023.110227","volume":"399","author":"O Youssef","year":"2023","unstructured":"Youssef, O. et al. Impact of the calcium concentration on the efficacy of phage phiIPLA-RODI, LysRODI\u0394Ami and nisin for the elimination of Staphylococcus aureus during lab-scale cheese production. Int. J. Food Microbiol. 399, 110227 (2023).","journal-title":"Int. J. Food Microbiol."},{"key":"4654_CR141","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102287","volume":"24","author":"MC Bichet","year":"2021","unstructured":"Bichet, M. C. et al. Bacteriophage uptake by mammalian cell layers represents a potential sink that may impact phage therapy. iScience 24, 102287 (2021).","journal-title":"iScience"},{"key":"4654_CR142","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/s41591-021-01403-9","volume":"27","author":"RM Dedrick","year":"2021","unstructured":"Dedrick, R. M. et al. Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection. Nat. Med. 27, 1357\u20131361 (2021).","journal-title":"Nat. Med."},{"key":"4654_CR143","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3389\/fmicb.2016.01681","volume":"7","author":"M \u017baczek","year":"2016","unstructured":"\u017baczek, M. et al. Antibody production in response to staphylococcal MS-1 phage cocktail in patients undergoing phage therapy. Front. Microbiol. 7, 1681 (2016).","journal-title":"Front. Microbiol."},{"key":"4654_CR144","doi-asserted-by":"crossref","unstructured":"Loh, B. et al. Encapsulation and delivery of therapeutic phages. Appl. Environ. Microbiol. 87, e01979-20 (2021).","DOI":"10.1128\/AEM.01979-20"},{"key":"4654_CR145","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/acssynbio.0c00402","volume":"10","author":"K Vogele","year":"2021","unstructured":"Vogele, K., Falgenhauer, E., von Sch\u00f6nberg, S., Simmel, F. C. & Pirzer, T. Small antisense DNA-based gene silencing enables cell-free bacteriophage manipulation and genome replication. ACS Synth. Biol. 10, 459\u2013465 (2021).","journal-title":"ACS Synth. Biol."},{"key":"4654_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46585-1","volume":"15","author":"A Levrier","year":"2024","unstructured":"Levrier, A. et al. PHEIGES: all-cell-free phage synthesis and selection from engineered genomes. Nat. Commun. 15, 2223 (2024).","journal-title":"Nat. Commun."},{"key":"4654_CR147","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.chembiol.2022.06.003","volume":"29","author":"Q Emslander","year":"2022","unstructured":"Emslander, Q. et al. Cell-free production of personalized therapeutic phages targeting multidrug-resistant bacteria. Cell Chem. Biol. 29, 1434\u20131445 (2022).","journal-title":"Cell Chem. Biol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04654-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04654-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04654-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:18:27Z","timestamp":1792102707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04654-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":147,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4654"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04654-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The competing interests declared below reflect the authors\u2019 disclosures during the development and up to the endorsement of this guideline by the participating societies. S.W. declares receiving third-party funding for research projects to the author\u2019s institution, with no direct personal payment, and being a founding member of Phage4-1Health (unpaid position) as well as elected member of the steering committee of the PhageNET DZIF (unpaid). S.L.J. received a maternity leave stipend from the German Center for Infection Research and a grant from the Fraunhofer Thera Nova Program as well as travel support to the ESCMID phage course in Lyon 2024 and receipt of equipment from the German Collection of Microorganisms and Cell Cultures (DSMZ). H.L. is an inventor on patents relating to Bacterial Vector (publication number: 20080112928), Pharmaceutical Composition for Tumor Treatment (publication number: 20100086557), Tumor-Specific Bacterial Promoter Elements (publication number: 20120244621) and Codon Optimization (publication number: 20190325989). P.J.C. reports institutional research funding through the PhageSafety (Institut Pasteur Network Grant) and EPHICACI (FWO Grant) research projects and serving as an unpaid member of the KLEOPATRA Advisory Board (JPIAMR grant), an unpaid lead of the EDQM Working Group on Bacteriophages, an unpaid member of the EUCAST Phage Susceptibility Testing (EUCAST-PST) Subcommittee and an unpaid board member of the Belgian Society for Viruses of Microbes. J.P.P. is employed by the Belgian Defense as statutory officer, and he received travel support (including registration fees, flights and accommodation) from several conference organizers and academic institutions, including the Global AMR R&D Hub, Riga Stradi\u0146\u0161 University, Argomenti di Malattie Infettive e Tropicali (AMIT), the Phage Therapy Congress and Lund University, for participation in scientific meetings and conferences. J.P.P. serves as unpaid Secretary of P-H-A-G-E.org; unpaid Science Officer of the ESCMID Study Group for Non-Traditional Antibacterial Therapy (ESGNTA); an unpaid member of the European Medicines Agency (EMA) Novel Therapies and Technologies Working Party Operational Expert Group on Bacteriophages, where he contributes to the development of guidance on the quality, safety and efficacy of bacteriophages as veterinary medicines; and as team leader of the NATO Science and Technology Organization project Reintroduction of Phage Therapy in Military Medicine. In addition, J.P.P. serves as Vice Chair Cross Reader for European Commission Horizon 2020 and Horizon Europe calls (paid). M.d.J. received a postdoctoral research grant through the SAPHETY project. M.d.J. participated in the development of these guidelines while employed at Sciensano and has been employed by Rime Bioinformatics, a French start-up specializing in phage genomics, since November 2024. S.M. reports academic research funding from The LOOP Zurich (mTORUS project), the University of Zurich Postdoctoral Grant, the Marie Sk\u0142odowska-Curie Innovative Training Network (VIROINF) and the Swiss National Science Foundation (SPIRIT project). S.M.C. received travel support to attend the IndoSwiss AMR Dialogue (Bangalore, 2023). S.M.C. serves as an unpaid advisory board member of the EPICACY project, an unpaid Executive Board member of the ESCMID Study Group for Non-Traditional Antibacterial Therapy (ESGNTA) and the International Society for Viruses of Microbes (ISVM) and as unpaid Project Coordinator of International Phagistry. L.L. reports research funding from The LOOP Zurich (mTORUS 2022) and received travel support to attend the 16th Annual Meeting of the German Society for Environmental Dentistry. C.W. reports research grants and consulting fees from Solventum, M\u00f6lnlycke, Delta G and Avaris. C.W. also received honoraria for lectures and presentations from Solventum and M\u00f6lnlycke. S.L. is a member of the PhageNET DZIF Steering Committee (unpaid). E.A.I. reports institutional research funding from the German Federal Ministry of Education and Research (BMBF), MetaSystems Hard & Software GmbH and the Federal State of Mecklenburg-Vorpommern (EFRE). E.A.I. receives inventor remuneration from the University of M\u00fcnster for patents licensed to Bruker. E.A.I. received personal honoraria for lectures and presentations from Shionogi, Pfizer and BD Biosciences, including travel support from Pfizer and BD Biosciences. E.A.I. also received personal honoraria for serving on the expert board of the Institute for Quality Assurance and Transparency in Healthcare (IQTIG) for the quality assurance program on sepsis diagnosis, treatment and follow-up. M.W. reports research grants from the German Federal Ministry of Education and Research (BMBF), the German Research Foundation (DFG), the Federal Joint Committee (G-BA), the German Federal Ministry of Health (BMG) as well as Biotest, Pantherna and Aptarion. M.W. received consulting fees from Biotest, Pantherna and Aptarion and personal honoraria for lectures and presentations from AstraZeneca, Chiesi, Insmed, Gilead, Pfizer and Boehringer Ingelheim. T. Faltus received personal remuneration from Springer Nature for authoring a review article on phage therapeutics and pharmaceutical legislation. P.R. reports grants from the DFG and received personal honoraria for lectures and presentations from AVOXA, PHOENIX Pharma and the German Pharmaceutical Society (DPhG) and travel support from AVOXA. P.R. serves in unpaid advisory roles on the Scientific Advisory Board of the Federal Chamber of Pharmacists (BAK), the Federal Institute for Drugs and Medical Devices (BfArM) and the Drug Commission of German Pharmacists (AMK). H.F. serves as an unpaid member of the Federal Weekly Conference on the Epidemiological Situation (EpiLag) at the Robert Koch Institute (RKI) and the Federal Working Group on Infection Surveillance (BLAG) at the RKI. H.F. is President of the German Association for the Control of Virus Diseases (DVV), a board member of the German Society for Hygiene and Microbiology (DGHM) and advisory board member of the German Society for Virology (GfV), and the State Representative for Schleswig-Holstein of the German Medical Association for Information Technology, Medical Informatics and eHealth (B\u00c4MI). M.W.P. serves as president for the Paul Ehrlich Society for Antiinfective Therapy (unpaid). U.M. received consulting fees and personal honoraria for lectures, presentations and educational activities from Austrianni. S.B. serves as an unpaid Speaker of the Special Interest Group \u2018Microbial Viruses\u2019 of the German Society for General and Applied Microbiology (VAAM). M.S. reports institutional research funding from Vertex Pharmaceuticals through an investigator-initiated research award. M.S. received consulting fees, personal honoraria for lectures, presentations and educational activities and travel support and served on advisory boards for Vertex Pharmaceuticals. M.S. serves as the President-Elect of the German Society for Pediatric Pulmonology (GPP) and as Chair of the German Cystic Fibrosis Research Council (FGM), both unpaid. J.B. reports research funding from the German Armed Forces CBRN Protection Program (B-Schutzprogramm) and the European Defence Fund (EDF) Resilience PHAGE project. J.J.B. received travel support from the EDF Resilience PHAGE project and serves in an unpaid leadership role within the EDF Resilience PHAGE consortium. M.K. received personal honoraria for lectures from the Medical Association of North Rhine (\u00c4rztekammer Nordrhein) and the Academy for Infectious Medicine (Akademie f\u00fcr Infektionsmedizin e.V.). P.T. reports institutional research funding from the Howard Hughes Medical Institute, the Ralph & Marian Falk Medical Research Trust and the Colton Center for Autoimmunity. T. Ferry reports institutional research funding from PHAXIAM. T. Ferry serves as the unpaid Clinical Officer of the ESCMID Study Group for Non-Traditional Antibacterial Therapy (ESGNTA). M.J.G.T.V. reports research grants from Merck Sharp & Dohme, Heel, Roche and Tillotts. M.J.G.T.V. received consulting fees from Gilead, Tillotts, Pfizer, BIOASTER, GlaxoSmithKline, Ecraid, Eumedica, Bactolife and PAION. M.J.G.T.V. also received personal honoraria for lectures, presentations and educational activities from the Academy for Infectious Medicine (Akademie f\u00fcr Infektionsmedizin), AstraZeneca, bioM\u00e9rieux, Biotest, COCS GmbH, the DGI, the European Society of Neurogastroenterology, the Falk Foundation, FomF GmbH, Gilead, GlaxoSmithKline, Helios Kliniken, the Hessian State Social Court (Hessisches Landessozialgericht), Infektio Forum, Janssen-Cilag, Klinikum Kassel, the State Medical Association of Hesse (Landes\u00e4rztekammer Hessen), LMU Kliniken, Merck Sharp & Dohme, Pfizer, Streamed Up, St. Vincent Hospital and Tillotts. A.Y.C. reports institutional research funding from the German Center for Infection Research (DZIF) and the Federal Ministry of Education and Research (BMFTR). A.Y.C. received personal honoraria for lectures from Roland Berger, Goethe University Frankfurt and the Academy for Infectious Medicine (Akademie f\u00fcr Infektionsmedizin e.V.). A.Y.C. received travel grants from ESCMID (2024 and 2025) and the Federation of European Microbiological Societies (FEMS) (2023). A.Y.C. serves as the unpaid Scientific Secretary of the EUCAST Subcommittee on Phage Susceptibility Testing as well as elected member of the steering committee of the PhageNET DZIF (unpaid). A.Y.C. is a member of the DGI, the German Society of Internal Medicine (DGIM), the German Society for Hematology and Medical Oncology\/Infectious Diseases Working Group (DGHO\/AGIHO) and the ESCMID Study Group for Non-Traditional Antibacterial Therapy (ESGNTA). A.D., O.K., I.K., H.B., M.C., S.H., C.R., W.B., O.H., R.L.K., M.D., J.H., R.K. and B.C. declare no competing interests. An overview of the competing interests of the full guideline group \u2018Personalized Bacteriophage Therapy\u2019 of the Association of the Scientific Medical Societies in Germany is published in Supplementary File\n                      \n                      . The evaluation and management of competing interests is detailed in the section \u2018Disclosure of interests and management of conflicts\u2019 (\n                      \n                      ).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}